Regulatory Aspects Towards Approval of Nanomedicine

Nanomedicines have been in the forefront of pharmaceutical research in the last decades, creating new challenges for research community, industry, and regulators. There is a strong demand for the fast development of scientific and technological tools to address unmet medical needs, thus improving human health care and life quality. Tremendous advances in the biomaterials and nanotechnology fields have prompted their use as promising tools to overcome important drawbacks, mostly associated to the non-specific effects of conventional therapeutic approaches. However, the wide range of application of nanomedicines demands a profound knowledge and characterization of these complex products. Their properties need to be extensively understood to avoid unpredicted effects on patients, such as potential immune reactivity. Research policy and alliances have been bringing together scientists, regulators, industry, and, more frequently in recent years, patient representatives and patient advocacy institutions. In order to successfully enhance the development of new technologies, improved strategies for research-based corporate organizations, more integrated research tools dealing with appropriate translational requirements aiming at clinical development, and proactive regulatory policies are essential in the near future. This review focuses on the most important aspects currently recognized as key factors for the regulation of nanomedicines, discussing the efforts under development by industry and regulatory agencies to promote their translation into the market.

  • Nanomedicine: Prospects, Risks and Regulatory Issues
  • Current , Future Applications and Regulatory challenges
  • Current , Future Applications and Regulatory challenges
  • Research Policy and Alliances
  • Regulatory Policies
  • Regulation of Nanomedicines

Related Conference of Regulatory Aspects Towards Approval of Nanomedicine

April 20-21, 2018

4th International Conference on Antibiotics: R&D, B2B

Las Vegas, Nevada, USA
April 26-27, 2018

11th European Biosimilars Congress

Rome, Italy
May 07-09, 2018

15th Annual European Pharma Congress

Frankfurt, Germany
June 04-05, 2018 | Baltimore, Maryland, USA

5th International Conference on Natural Products & Marine Drugs

June 20-22, 2018

7th World Congress on Mass Spectrometry

Rome, Italy
July 18-19, 2018

12th Global
Pharmacovigilance & Clinical Trials Summit

Sydney, Australia
July 18-20, 2018

15th Asia-Pacific Pharma Congress

Melbourne, Australia
Jul 30-Aug 01, 2018

10th World Congress on Pharmacology

Barcelona, Spain
August 15-17, 2018

14th World Congress on Pharmacology and Drug Safety

Stockholm, Sweden
September 13-14, 2018

8th World Congress on Chromatography

Prague, Czech Republic
September 14-15, 2018

Annual Neurochemistry and Neuropharmacology Congress

Richmond, USA
September 17-18, 2018

15th International Conference on Pharmaceutical Formulations & Drug Delivery

| Philadelphia, Pennsylvania, USA
September 17-18, 2018

Drug formulation Congress 2018

Singapore
September 20-22, 2018

17th Annual Congress on Pharmaceutics & Novel Drug Delivery Systems

Prague, Czech Republic
September 24-26, 2018

7th International Conference on Clinical Trials

Chicago, USA
(10 Plenary Forums - 1 Event)
September 24-25, 2018

Pharmacoepidemiology 2018

Dubai, UAE
September 24-25, 2018

12th World Drug Delivery Summit

(10 Plenary Forums - 1Event)
Chicago, Illinois, USA
August 24-25, 2018

7th Global Advances in Mass Spectrometry

Singapore
October 24-25, 2018

13th International Conference on Biopharma and Biotherapeutics

Boston, Massachusetts, USA
November 05-06, 2018

18th Annual Pharmaceutical Chemical Analysis Congress

Madrid, Spain
November 15-16, 2018

9th Global Experts Meeting on Neuropharmacology

Frankfurt, Germany

Regulatory Aspects Towards Approval of Nanomedicine Conference Speakers

Recommended Sessions

Related Journals

Are you interested in